May 8 (Reuters) - Pfizer ( PFE ) has agreed to settle

more than 10,000 lawsuits about cancer risks related to the now

discontinued heartburn drug Zantac, Bloomberg News reported on

Wednesday, citing people familiar with the deal.

The agreements cover cases in U.S. state courts but don't

completely resolve the company's exposure to Zantac claims, the

report said, adding that financial details of the deals were not

immediately available.

Pfizer ( PFE ) did not immediately respond to a Reuters request for

comment.

In 2020, the U.S. Food and Drug Administration asked

drugmakers to pull Zantac and its generic versions off the

market after a cancer-causing substance called NDMA was found in

samples of the drug.

Thousands of lawsuits began piling up in federal and state

courts against Pfizer ( PFE ), GSK, Sanofi and

Boehringer Ingelheim.